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Purpose of the study
To compare the safety and efficacy of lopinavir/ritonavir
and nelfinavir-based regimens in HIV-1 infected pregnant
women.
Methods
A prospective cohort study to evaluate HIV mother-to-
child transmission. The study took place at 13 Spanish
hospitals. We reviewed the records of all pregnant women
treated with NFV (NCR) or LOP/r-containing (LOP/r CR)
regimens during pregnancy from May 2001 to December
2007. Drug selection was up to the physician. Abnormal-
ities were graded according to the National Institute of
Allergy and Infectious Disease Division of AIDS toxicity
guidelines. Data of mother and their children were
recorded following a standard protocol.
Summary of results
355 mothers were enrolled: mean age 31 years; Caucasian
74%; HCV co-infection 34%; 13% were on C3 according
to CDC category; heterosexual transmission 64%. 40%
received antiretroviral therapy for the first time during
pregnancy. 121 (34%) were on LOP/r CR and 234 (66%)
on NCR. Baseline characteristics, side-effects and discon-
tinuation of LPV or NFV of both groups are shown in
Table 1 (values are expressed as the median [IQR] for con-
tinuous variables and as N [%] for categorical variables).
No aminotransferases abnormalities (grade 3–4) or clini-
cal hepatitis were observed. There were no differences in
both groups according to weight and gestational age of the
babies at delivery. There was a case of vertical transmis-
sion (a mother treated with NFV and viral load above
500,000 copies/ml).
Conclusion
In our cohort lopinavir/ritonavir and nelfinavir-based reg-
imens during pregnancy were safe, effective and well tol-
erated.
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Age (yr) 32 (28–36) 32 (26–36) NS
C3 category 21 (10) 21 (19) 0,026
CD4 (cells/μL) at 1st visit 477 (325–652) 426 (264–600) NS
Viral load < 50 copies/ml at 3rd trimester 142 (70) 61 (62) NS
Hepatitis C 79 (35) 40 (33) NS
HAART-naive patients 108 (48) 35 (29) 0.001
Gestational diabetes mellitus 15 (8) 5 (5) NS
Vomiting 9 (4) 16 (14) <0.001
Diarrhoea 27 (12) 15 (14) NS
Discontinuation of LPV or NFV. 23 (10) 12 (10) NS
Discontinuation of LPV or NFV due to virologic failure. 1 (0.4) 1 (0.8) NS
Vertical transmission 1 (0.4) 0 NSPage 2 of 2
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